Floatz logo

Irinotecan

Uterine Corpus Carcinosarcoma

Mayo ClinicSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Uterine Corpus Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Cediranib
Mayo Clinic
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Metformin
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC
Doxycycline
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC
(+)-VINCRISTINE
Mayo Clinic
Phase 1CC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →